Epiprotect® Demonstrates Significantly Lower Infection Risk in Major Pediatric Study

An independent study published in the Journal of Plastic, Reconstructive & Aesthetic Surgery, conducted at Nottingham Children’s Hospital, shows positive results for Epiprotect®. The study highlights significant pain relief, safety, and quick and easy patient follow-ups. Involving 99 patients aged 0 - 18 years treated for partial-thickness burns, the study reveals that Epiprotect® has comparable acute healing outcomes to Biobrane® from Smith & Nephew, but with a significantly lower infection rate (2.6% compared to 16.4%).

"It is highly significant for S2Medical that high-quality studies like this confirm the benefits we have experienced during our journey to introduce Epiprotect® to the global market. That Epiprotect® now proves to reduce infection risks compared to one of the previously leading products is an enormously important finding, especially since infections in children can mean the difference between life and death," says the company's CEO, Petter Sivlér.

The company expects that the results will accelerate the commercialization of Epiprotect products, leading to increased royalty revenues and enhancing the potential for additional payments for Epiprotect.

This disclosure contains information that S2Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 20-06-2024 10:32 CET.

Contact Details
Petter Sivlér – CEO, S2Medical AB (publ)
Telephone: +46 (0)8-70 000 50
E-mail: petter.sivler@s2m.se

Certified Adviser
Vator Securities AB
Telephone +46 (0)8-580 065 99
Website: www.vatorsec.se 
E-mail: ca@vatorsec.se

About S2Medical 

S2Medical AB (publ) is a medical technology company that develops and sells innovative wound healing products for the entire wound healing process. The company offers advanced solutions with a particular focus on the treatment of burns and chronic wounds. S2Medical aims to reduce patient suffering and healthcare costs through groundbreaking technology and clinical expertise. Among the company's products are IvaQ, a system for negative pressure wound therapy, Instagraft for skin transplantation, and antimicrobial peptides for treating multi-resistant bacteria.

Share's ticker: S2M

Share's ISIN-code: SE0011725084